When Kristen Criss was diagnosed with hypertrophic cardiomyopathy (HCM), it felt like the pieces of her family's health puzzle had finally fallen into place. "My mom passed at 40-years-old, and my ...

Hypertrophic cardiomyopathy (HCM) is a chronic, inheritable disease where there is excessive thickening of the heart muscle. The most frequent cause of HCM is the presence of mutations in sarcomere ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced initial dosing in a Phase 1 trial of EDG-7500.

Edgewise Therapeutics (EWTX) added ~17% on Wednesday after the Boulder, Colorado-based biopharma updated data from a mid-stage trial for EDG-7500, its experimental therapy for a genetic heart disorder ...

Please provide your email address to receive an email when new articles are posted on . A first-in-human phase 1 trial is testing a novel gene therapy for hypertrophic cardiomyopathy. The one-time ...

A joint effort by a team of academic and industrial researchers led by Associate Professor Yoshinori Yoshida (Department of Cell Growth and Differentiation) created a new modeling system, combining ...

BACKGROUND: Sarcomere gene variants are a key cause of hypertrophic cardiomyopathy (HCM), and have been associated with worse prognosis. However, it is unclear how comorbidities influence clinical ...

Future Cardiol. 2013;9(5):697-709. Geometry Asymmetric hypertrophy out of proportion to hypertension Concentric remodeling or hypertrophy Symmetric LV hypertrophy that is proportional to exercise ...

Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor ...